Cargando…
P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430329/ http://dx.doi.org/10.1097/01.HS9.0000973044.21308.32 |
| _version_ | 1785090936993218560 |
|---|---|
| author | Birndt, Sebastian Hammersen, Jakob Döhner, Konstanze Reuken, Philipp Sauerbrey, Paul Rosée, Felicitas La Pfirrmann, Markus Fabisch, Christian Illerhaus, Gerald Weiß, Manfred Träger, Karl Bremer, Hinrich Drömann, Daniel Schneider, Sylke Rosee, Paul La Hochhaus, Andreas |
| author_facet | Birndt, Sebastian Hammersen, Jakob Döhner, Konstanze Reuken, Philipp Sauerbrey, Paul Rosée, Felicitas La Pfirrmann, Markus Fabisch, Christian Illerhaus, Gerald Weiß, Manfred Träger, Karl Bremer, Hinrich Drömann, Daniel Schneider, Sylke Rosee, Paul La Hochhaus, Andreas |
| author_sort | Birndt, Sebastian |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430329 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104303292023-08-17 P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL Birndt, Sebastian Hammersen, Jakob Döhner, Konstanze Reuken, Philipp Sauerbrey, Paul Rosée, Felicitas La Pfirrmann, Markus Fabisch, Christian Illerhaus, Gerald Weiß, Manfred Träger, Karl Bremer, Hinrich Drömann, Daniel Schneider, Sylke Rosee, Paul La Hochhaus, Andreas Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430329/ http://dx.doi.org/10.1097/01.HS9.0000973044.21308.32 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Birndt, Sebastian Hammersen, Jakob Döhner, Konstanze Reuken, Philipp Sauerbrey, Paul Rosée, Felicitas La Pfirrmann, Markus Fabisch, Christian Illerhaus, Gerald Weiß, Manfred Träger, Karl Bremer, Hinrich Drömann, Daniel Schneider, Sylke Rosee, Paul La Hochhaus, Andreas P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL |
| title | P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL |
| title_full | P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL |
| title_fullStr | P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL |
| title_full_unstemmed | P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL |
| title_short | P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL |
| title_sort | p1542: ruxolitinib in covid-19 patients with defined hyperinflammation: the ruxcoflam trial |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430329/ http://dx.doi.org/10.1097/01.HS9.0000973044.21308.32 |
| work_keys_str_mv | AT birndtsebastian p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT hammersenjakob p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT dohnerkonstanze p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT reukenphilipp p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT sauerbreypaul p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT roseefelicitasla p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT pfirrmannmarkus p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT fabischchristian p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT illerhausgerald p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT weißmanfred p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT tragerkarl p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT bremerhinrich p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT dromanndaniel p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT schneidersylke p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT roseepaulla p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial AT hochhausandreas p1542ruxolitinibincovid19patientswithdefinedhyperinflammationtheruxcoflamtrial |